logo
  

Inovio Says Preclinical Studies Show INO-4802 Effective Against COVID-19 Variants - Quick Facts

Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Wednesday that its next-generation Pan-SARS-CoV-2 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses in preclinical models against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant).

These results demonstrate the potential of Inovio's Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a booster for individuals previously immunized with various Wuhan-matched vaccines.

Inovio's Pan-COVID-19 vaccine approach is designed to provide cross-strain protection, immune coverage, reduced susceptibility to escape mutants, and non-restricted geographical use against both known and potentially unknown variants.

Preclinical data with INO-4802 in multiple models revealed both broader and increased levels of neutralizing antibodies against a panel of variants than strain-matched vaccines. Building on this initial work, Inovio plans to conduct Phase 1/2 clinical trials this year with INO-4802.

The next-generation Pan-COVID-19 variant vaccine candidate is expected to enter a global Phase 3 trial this summer.

To create Inovio's Pan-COVID-19 vaccine candidate, variant sequences were identified over a four-month period starting in October 2020 from multiple geographic regions - Brazil, Canada, India, Italy, Japan, Nigeria, South Africa, United Kingdom, and the United States.

The mutations in the spike sequences were aggregated for each region. The sequence results from these regions were then further engineered to determine a common set of overlapping mutations from emerging variations in the COVID spike protein sequences to generate INO-4802.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Department store chain Sears is closing down its last store located in its home state of Illinois, CNBC reported. The company, which was founded in Chicago in 1892, plans to shut the shop, located in Simon Property Group's Woodfield Mall, on November 14. Sears' parent company, Transformco, which also manages the real estate, said it plans to maximize the value of the Woodfield Mall property and Amazon said over 1 million people have applied for a job at the tech major as part of its Career Day 2021. Job seekers from more than 170 countries have participated in the virtual event. In addition, more than 2,000 Amazon recruiters offered 30,000 individual career coaching sessions with participants in a single day.
Follow RTT